CCIA
AIMT

Campbell & Co Investment Adviser’s Aimmune Therapeutics AIMT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,459
Closed -$283K – 619
2019
Q4 		$283K Buy
+8,459
New +$236K 0.09% 441

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Campbell & Co Investment Adviser's AIMT Position: Q1 2020 in Review

Campbell & Co Investment Adviser sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 8,459 shares — an estimated $283K sold.

Campbell & Co Investment Adviser first reported a position in AIMT in Q4 2019 and held it in 1 quarter. The position peaked at $283K in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • Campbell & Co Investment Adviser reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 8,459 Aimmune Therapeutics shares in Q1 2020, an estimated $283K.
  • Campbell & Co Investment Adviser first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Aimmune Therapeutics position peaked at $283K in Q4 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2020, filed 29 Apr 2020.